The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease

Brain Research Reviews

Volumn 59, Issue 2, 2009, Pages 410-431

  Gil, Joana M ^a   Rego, A Cristina ^b  

^a UNIVERSITY OF VICTORIA   (Canada)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Behavioral deficit; Huntington's disease; Neuropathology; R6 1 and R6 2 transgenic mice; Survival; Therapy

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 2',3',5' TRI O ACETYLURIDINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ACETYLSALICYLIC ACID; ANTIOXIDANT; ASCORBIC ACID; BUTYRIC ACID; CASPASE; CEFTRIAXONE; CHROMOMYCIN; CLIOQUINOL; CYSTAMINE; ESSENTIAL FATTY ACID; HISTONE; HUNTINGTIN; KP 544; LITHIUM; MINOCYCLINE; MITHRAMYCIN; PN 401; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PYRIMIDINE NUCLEOSIDE DERIVATIVE; REMACEMIDE; RILUZOLE; THIOCTIC ACID; TIAGABINE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

BRAIN CORTEX; CORPUS STRIATUM; DEACETYLATION; DIABETES MELLITUS; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; EXCITOTOXICITY; GENE; GENETIC MANIPULATION; HD GENE; HUMAN; HUNTINGTON CHOREA; METHYLATION; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OLIGOMERIZATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; REVIEW; SYMPTOMATOLOGY; TRANSGENIC MOUSE;

ANIMALS; BRAIN; BRAIN CHEMISTRY; BRAIN TISSUE TRANSPLANTATION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENE THERAPY; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS;

EID: 60549103857     PISSN: 01650173     EISSN: 18726321     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2008.12.001     Document Type: Review

References (158)

1. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R., Hersch S.M., Ross C.A., and Beal M.F. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8 (2001) 479-491
2. Andreassen O.A., Ferrante R.J., Dedeoglu A., and Beal M.F. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. NeuroReport 12 (2001) 3371-3373
3. Andreassen O.A., Ferrante R.J., Huang H.M., Dedeoglu A., Park L., Ferrante K.L., Kwon J., Borchelt D.R., Ross C.A., Gibson G.E., and Beal M.F. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann. Neurol. 50 (2001) 112-117
4. Andreassen O.A., Dedeoglu A., Stanojevic V., Hughes D.B., Browne S.E., Leech C.A., Ferrante R.J., Habener J.F., Beal M.F., and Thomas M.K. Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol. Dis. 11 (2002) 410-424
5. Apostol B.L., Simmons D.A., Zuccato C., Illes K., Pallos J., Casale M., Conforti P., Ramos C., Roarke M., Kathuria S., Cattaneo E., Marsh J.L., and Thompson L.M. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol. Cell. Neurosci. 39 (2008) 8-20
6. Arivazhagan P., Ramanathan K., and Panneerselvam C. Effect of DL-alpha-lipoic acid on glutathione metabolic enzymes in aged rats. Exp. Gerontol. 37 (2001) 81-87
7. Bae B.I., Xu H., Igarashi S., Fujimuro M., Agrawal N., Taya Y., Hayward S.D., Moran T.H., Montell C., Ross C.A., Snyder S.H., and Sawa A. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47 (2005) 29-41
8. Benchoua A., Trioulier Y., Zala D., Gaillard M.C., Lefort N., Dufour N., Saudou F., Elalouf J.M., Hirsch E., Hantraye P., Déglon N., and Brouillet E. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol. Biol. Cell 17 (2006) 1652-1663
9. Benraiss A., Chmielnicki E., Lerner K., Roh D., and Goldman S.A. Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain. J. Neurosci. 21 (2001) 6718-6731
10. Bensimon G., and Doble A. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opin. Drug Saf. 3 (2004) 525-534
11. Björkqvist M., Fex M., Wierup N., Petersén Å., Gil J., Bacos K., Popovic N., Li J.Y., Sundler F., Brundin P., and Mulder H. The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient β-cell mass. Hum. Mol. Genet. 14 (2005) 565-574
12. Björkqvist M., Petersén Å., Bacos K., Isaacs J., Norlén P., Gil J., Popovic N., Sundler F., Bates G.P., Tabrizi S.J., Brundin P., and Mulder H. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 15 (2006) 1713-1721
13. Bolivar V.J., Manley K., and Messer A. Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice. Behav. Neurosci. 117 (2003) 1233-1242
14. Bolivar V.J., Manley K., and Messer A. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice. Brain Res. 1005 (2004) 29-35
15. Bonelli R.M., Hödl A.K., Hofmann P., and Kapfhammer H.P. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int. Clin. Psychopharmacol. 19 (2004) 337-342
16. Borrell-Pagès M., Canals J.M., Cordelières F.P., Parker J.A., Pineda J.R., Grange G., Bryson E.A., Guillermier M., Hirsch E., Hantraye P., Cheetham M.E., Néri C., Alberch J., Brouillet E., Saudou F., and Humbert S. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest. 116 (2006) 1410-1424
17. Canals J.M., Pineda J.R., Torres-Peraza J.F., Bosch M., Martín-Ibañez R., Muñoz M.T., Mengod G., Ernfors P., and Alberch J. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 24 (2004) 7727-7739
18. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. Neuroscience 19 (1999) 3248-3257
19. Carter R.J., Hunt M.J., and Morton A.J. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov. Disord. 15 (2000) 925-937
20. Cha J.H. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23 (2000) 387-392
21. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., and Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6480-6485
22. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrel L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., and Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delaus mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6 (2000) 797-801
23. Cho S.R., Benraiss A., Chmielnicki E., Samdani A., Economides A., and Goldman S.A. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J. Clin. Invest. 117 (2007) 2889-2902
24. Chopra V., Fox J.H., Lieberman G., Dorsey K., Matson W., Waldmeier P., Housman D.E., Kazantsev A., Young A.B., and Hersch S. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 16685-16689
25. Chou S.Y., Lee Y.C., Chen H.M., Chiang M.C., Lai H.L., Chang H.H., Wu Y.C., Sun C.N., Chien C.L., Lin Y.S., Wang S.C., Tung Y.Y., Chang C., and Chern Y. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 93 (2005) 310-320
26. Clifford J.J., Drago J., Natoli A.L., Wong J.Y.F., Kinsella A., Waddington J.L., and Vaddadi K.S. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 109 (2002) 81-88
27. Conforti P., Ramos C., Apostol B.L., Simmons D.A., Nguyen H.P., Riess O., Thompson L.M., Zuccato C., and Cattaneo E. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Mol. Cell. Neurosci. 39 (2008) 1-7
28. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., and Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997) 537-548
29. Dedeoglu A., Kubilus J.K., Jeitner T.M., Matson S.A., Bogdanov M., Kowall N.W., Matson W.R., Cooper A.J.L., Ratan R.R., Beal M.F., Hersch S.M., and Ferrante R.J. Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22 (2002) 8942-8950
30. Dedeoglu A., Kubilus J.K., Yang L., Ferrante K.L., Hersch S.M., Beal M.F., and Ferrante R.J. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem. 85 (2003) 1359-1367
31. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., Lees A.J., Jenner P., and Marsden C.D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 (1991) 1953-1975
32. Dey N.D., Boersen A.J., Myers R.A., York L.R., Bombard M.C., Lu M., Sandstrom M.I., Hulce V.D., Lescaudron L., and Dunbar G.L. The novel substituted pyrimidine, KP544, reduces motor deficits in the R6/2 transgenic mouse model of Huntington's disease. Restor. Neurol. Neurosci. 25 (2007) 485-492
33. DiFiglia M., Sena-Esteves M., Chase K., Sapp E., Pfister E., Sass M., Yoder J., Reeves P., Pandey R.K., Rajeev K.G., Manoharan M., Sah D.W., Zamore P.D., and Aronin N. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 17204-17209
34. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 47 (1996) S233-S241
35. Domenici M.R., Scattoni M.L., Martire A., Lastoria G., Potenza R.L., Borioni A., Venerosi A., Calamandrei G., and Popoli P. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol. Dis. 28 (2007) 197-205
36. Duan W., Peng Q., Masuda N., Ford E., Tryggestad E., Ladenheim B., Zhao M., Cadet J.L., Wong J., and Ross C.A. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol. Dis. 30 (2008) 312-322
37. Dunnett S.B., Carter R.J., Watts C., Torres E.M., Mahal A., Mangiarini L., Bates G., and Morton A.J. Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp. Neurol. 154 (1998) 31-40
38. Erbayraktar S., Grasso G., Sfacteria A., Xie Q.W., Coleman T., Kreilgaard M., Torup L., Sager T., Erbayraktar Z., Gokmen N., Yilmaz O., Ghezzi P., Villa P., Fratelli M., Casagrande S., Leist M., Helboe L., Gerwein J., Christensen S., Geist M.A., Pedersen L.Ø., Cerami-Hand C., Wuerth J.P., Cerami A., and Brines M. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6741-6746
39. Farrer L.A. Diabetes mellitus in Huntington disease. Clin. Genet. 27 (1985) l62-167
40. Feigin A., Kieburtz K., Como P., Hickey C., Claude K., Abwender D., Zimmerman C., Steinberg K., and Shoulson I. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov. Disord. 11 (1996) 321-323
41. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., and Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20 (2000) 4389-4397
42. 10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22 (2002) 1592-1599
43. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., Smith K., Kowall N.W., Ratan R.R., Luthi-Carter R., and Hersch S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23 (2003) 9418-9427
44. Ferrante R.J., Ryu H., Kubilus J.K., D, Mello S., Sugars K.L., Lee J., Lu P., Smith K., Browne S., Beal M.F., Kristal B.S., Stavrovskaya I.G., Hewett S., Rubinsztein D.C., Langley B., and Ratan R.R. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci. 24 (2004) 10335-10342
45. Forloni G., Colombo L., Girola L., Tagliavini F., and Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 487 (2001) 404-487
46. Gil J.M., and Rego A.C. Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 27 (2008) 2803-2820
47. Gil J.M., Leist M., Popovic N., Brundin P., and Petersén Å. Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice. BMC Neurosci. 5 (2004) 17-27
48. Gil J.M., Mohapel P., Araújo I.M., Popovic N., Li J.Y., Brundin P., and Petersén Å. Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice. Neurobiol. Dis. 20 (2005) 744-751
49. Glass M., Dragunow M., and Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97 (2000) 505-519
50. Glass M., van Dellen A., Blakemore C., Hannan A.J., and Faull R.L. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 123 (2004) 207-212
51. Gould E., Beylin A., Tanapat P., Reeves A., and Shors T.J. Learning enhances adult neurogenesis in the hippocampal formation. Nat. Neurosci. 2 (1999) 260-265
52. Grote H.E., Bull N.D., Howard M.L., van Dellen A., Blakemore C., Bartlett P.F., and Hannan A.J. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur. J. Neurosci. 22 (2005) 2081-2088
53. Hagen T.M., Ingersoll R.T., Lykkesfeldt J., Liu J., Wehr C.M., Vinarsky V., Bartholomew J.C., and Ames A.B. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J. 13 (1999) 411-418
54. Hannan A.J. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease. Acta Biochim. Pol. 51 (2004) 415-430
55. Hansson O., Nylandsted J., Castilho R.F., Leist M., Jäättelä M., and Brundin P. Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. Brain Res. 970 (2003) 47-57
56. Heiser V., Scherzinger E., Boeddrich A., Nordhoff E., Lurz R., Schugardt N., Lehrach H., and Wanker E.E. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6739-6744
57. Helmlinger D., Yvert G., Picaud S., Merienne K., Sahel J., Mandel J.L., and Devys D. Progressive retinal degeneration and dysfunction in R6 Huntington's disease mice. Hum. Mol. Genet. 11 (2002) 3351-3359
58. Hemmer W., and Wallimann T. Functional aspects of creatine kinase in brain. Dev. Neurosci. 15 (1993) 249-260
59. Hickey M.A., Gallant K., Gross G.G., Levine M.S., and Chesselet M.F. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol. Dis. 20 (2005) 1-11
60. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., Lewis C.M., Hannan A.J., and Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 51 (2002) 235-242
61. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., Sathasivam K., Ghazi-Noori S., Mahal A., Lowden P.A., Steffan J.S., Marsh J.L., Thompson L.M., Lewis C.M., Marks P.A., and Bates G.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2041-2046
62. Hockly E., Woodman B., Mahal A., Lewis C.M., and Bates G. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res. Bull. 61 (2003) 469-479
63. Hockly E., Tse J., Barker A.L., Moolman D.L., Beunard J.L., Revington A.P., Holt K., Sunshine S., Moffitt H., Sathasivam K., Woodman B., Wanker E.E., Lowden P.A., and Bates G.P. Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiol. Dis. 21 (2006) 228-236
64. Huang B., Schiefer J., Sass C., Landwehrmeyer G.B., Kosinski C.M., and Kochanek S. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum. Gene Ther. 18 (2007) 303-311
65. Hunt M.J., and Morton A.J. Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp. Brain Res. 166 (2005) 220-229
66. 10 and remacemide in Huntington's disease. Neurology 57 (2001) 397-404
67. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 61 (2003) 1551-1556
68. Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology 63 (2004) 547-549
69. Hurlbert M.S., Zhou W., Wasmeier C., Kaddis F.G., Hutton J.C., and Freed C.R. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48 (1999) 649-651
70. Iannicola C., Moreno S., Oliverio S., Nardacci R., Ciofi-Luzzatto A., and Piacentini M. Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease. J. Neurochem. 75 (2000) 830-839
71. Jin K., LaFevre-Bernt M., Sun Y., Chen S., Gafni J., Crippen D., Logvinova A., Ross C.A., Greenberg D.A., and Ellerby L.M. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18189-18194
72. Johansson B.B. Functional outcome in rats transferred to an enriched environment 15 days after focal brain ischemia. Stroke 27 (1996) 324-326
73. Kahlem P., Green H., and Djian P. Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol. Cell 1 (1998) 595-601
74. Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S., Pedotti R., Mitchell D., and Steinman L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8 (2002) 143-149
75. Keene C.D., Rodrigues C.M., Eich T., Chhabra M.S., Steer C.J., and Low W.C. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10671-10676
76. Kempermann G., Kuhn H.G., and Gage F.H. More hippocampal neurons in adult mice living in an enriched environment. Nature 386 (1997) 493-495
77. Klivenyi P., Ferrante R.J., Gardian G., Browne S., Chabrier P.E., and Beal M.F. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J. Neurochem. 86 (2003) 267-272
78. Klunk W.E., Pettegrew J.W., and Abraham D.J. Quantitative evaluation of Congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem. 37 (1989) 1273-1281
79. Kohl Z., Kandasamy M., Winner B., Aigner R., Gross C., Couillard-Despres S., Bogdahn U., Aigner L., and Winkler J. Physical activity fails to rescue hippocampal neurogenesis deficits in the R6/2 mouse model of Huntington's disease. Brain Res. 1155 (2007) 24-33
80. Landwehrmeyer G.B., Dubois B., de Yébenes J.G., Kremer B., Gaus W., Kraus P.H., Przuntek H., Dib M., Doble A., Fischer W., Ludolph A.C., and European Huntington's Disease Initiative Study Group. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann. Neurol. 62 (2007) 262-272
81. Lazic S.E., Grote H., Armstrong R.J., Blakemore C., Hannan A.J., van Dellen A., and Barker R.A. Decreased hippocampal cell proliferation in R6/1 Huntington's mice. NeuroReport 15 (2004) 811-813
82. Lazic S.E., Grote H.E., Blakemore C., Hannan A.J., van Dellen A., Phillips W., and Barker R.A. Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur. J. Neurosci. 23 (2006) 1829-1838
83. Li H., Li S.H., Cheng A.L., Mangiarini L., Bates G.P., and Li X.J. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum. Mol. Genet. 8 (1999) 1227-1236
84. Lindvall O., Kokaia Z., and Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat. Med. 10 (2004) S42-S50
85. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., and Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 19 (1999) 10428-10437
86. Luesse H.G., Schiefer J., Spruenken A., Puls C., Block F., and Kosinski C.M. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Behav. Brain Res. 126 (2001) 185-195
87. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.H., and Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9 (2000) 1259-1271
88. Luthi-Carter R., Hanson S.A., Strand A.D., Bergstrom D.A., Chun W., Peters N.L., Woods A.M., Chan E.Y., Kooperberg C., Krainc D., Young A.B., Tapscott S.J., and Olson J.M. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 11 (2002) 1911-1926
89. Luthi-Carter R., Apostol B.L., Dunah A.W., DeJohn M.M., Farrell L.A., Bates G.P., Young A.B., Standaert D.G., Thompson L.M., and Cha J.H. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiol. Dis. 14 (2003) 624-636
90. Ma T.C., Buescher J.L., Oatis B., Funk J.A., Nash A.J., Carrier R.L., and Hoyt K.R. Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci. Lett. 411 (2007) 98-103
91. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
92. Mastroberardino P.G., Iannicola C., Nardacci R., Bernassola F., De Laurenzi V., Melino G., Moreno S., Pavone F., Oliverio S., Fesus L., and Piacentini M. Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ. 9 (2002) 873-880
93. Masuda N., Peng Q., Li Q., Jiang M., Liang Y., Wang X., Zhao M., Wang W., Ross C.A., and Duan W. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiol. Dis. 30 (2008) 293-302
94. Meade C.A., Deng Y.P., Fusco F.R., Del Mar N., Hersch S., Goldowitz D., and Reiner A. Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice. J. Comp. Neurol. 449 (2002) 241-269
95. Miller T.W., Shirley T.L., Wolfgang W.J., Kang X., and Messer A. DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol. Ther. 7 (2003) 572-579
96. Miller B.R., Dorner J.L., Shou M., Sari Y., Barton S.J., Sengelaub D.R., Kennedy R.T., and Rebec G.V. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 153 (2008) 329-337
97. Morton A.J., Hunt M.J., Hodges A.K., Lewis P.D., Redfern A.J., Dunnett S.B., and Jones L. A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. Eur. J. Neurosci. 21 (2005) 855-870
98. Morton A.J., Wood N.I., Hastings M.H., Hurelbrink C., Barker R.A., and Maywood E.S. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J. Neurosci. 25 (2005) 157-163
99. Murphy K.P., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease gene. J. Neurosci. 20 (2000) 5115-5123
100. Nguyen T., Hamby A., and Massa S.M. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 1840-11845
101. Norflus F., Nanje A., Gutekunst C.A., Shi G., Cohen J., Bejarano M., Fox J., Ferrante R.J., and Hersch S.M. Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. Neurobiol. Dis. 17 (2004) 319-325
102. Ona V.O., Li M., Vonsattel J.P.G., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.J., Stieg P.E., Yuan J., Penney J.B., Young A.B., Cha J.H., and Friedlander R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399 (1999) 263-267
103. Pallier P.N., Maywood E.S., Zheng Z., Chesham J.E., Inyushkin A.N., Dyball R., Hastings M.H., and Morton A.J. Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J. Neurosci. 27 (2007) 7869-7878
104. Pencea V., Bingaman K.D., Wiegand S.J., and Luskin M.B. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J. Neurosci. 21 (2001) 6706-6717
105. Peng Q., Masuda N., Jiang M., Li Q., Zhao M., Ross C.A., and Duan W. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp. Neurol. 210 (2008) 154-163
106. Petersén Å., and Björkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur. J. Neurosci. 24 (2006) 961-967
107. Petersén Å., Gil J., Maat-Schieman M.L.C., Björkqvist M., Tanila H., Araújo I.M., Smith R., Popovic N., Wierup N., Norlén P., Li J.Y., Roos R.A.C., Sundler F., Mulder H., and Brundin P. Orexin loss in Huntington's disease. Hum. Mol. Genet. 14 (2005) 39-47
108. Pineda J.R., Rubio N., Akerud P., Urbán N., Badimon L., Arenas E., Alberch J., Blanco J., and Canals J.M. Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: optical neuroimage tracking of brain-grafted cells. Gene Ther. 14 (2007) 118-128
109. Podolsky S., Leopold N.A., and Sax D.S. Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1 (1972) 1356-1358
110. Popovic N., Maingay M., Kirik D., and Brundin P. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Exp.Neurol. 193 (2005) 65-74
111. Rebec G.V., Barton S.J., and Ennis M.D. Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene. J. Neurosci. 22 (2002) RC202
112. Rebec G.V., Barton S.J., Marseilles A.M., and Collins K. Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuroreport 14 (2003) 1263-1265
113. Rebec G.V., Conroy S.K., and Barton S.J. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment. Neuroscience 137 (2006) 327-336
114. Rosas H.D., Koroshetz W.J., Jenkins B.G., Chen Y.I., Hayden D.L., Beal M.F., and Cudkowicz M.E. Riluzole therapy in Huntington's disease (HD). Mov. Disord. 14 (1999) 326-330
115. Ross C.A., and Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 10 (2004) S10-S17
116. Ryu H., Lee J., Hagerty S.W., Soh B.Y., McAlpin S.E., Cormier K.A., Smith K.M., and Ferrante R.J. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. USA 103 (2006) 19176-19181
117. Sánchez I., Mahlke C., and Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421 (2003) 373-379
118. Saydoff J.A., Liu L.S., Garcia R.A., Hu Z., Li D., and von Borstel R.W. Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease. Brain Res. 994 (2003) 44-54
119. Saydoff J.A., Garcia R.A., Browne S.E., Liu L., Sheng J., Brenneman D., Hu Z., Cardin S., Gonzalez A., von Borstel R.W., Gregorio J., Burr H., and Beal M.F. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiol. Dis. 24 (2006) 455-465
120. Scarabelli T.M., Stephanou A., Pasini E., Gitti G., Townsend P., Lawrence K., Chen-Scarabelli C., Saravolatz L., Latchman D., Knight R., and Gardin J. Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J. Am. Coll. Cardiol. 43 (2004) 865-874
121. Schiefer J., Landwehrmeyer G.B., Lüesse H.G., Sprünken A., Puls C., Milkereit A., Milkereit E., and Kosinski C.M. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov. Disord. 17 (2002) 748-757
122. Schiefer J., Sprünken A., Puls C., Lüesse H.G., Milkereit A., Milkereit E., Johann V., and Kosinski C.M. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res. 1019 (2004) 246-254
123. Seppi K., Mueller J., Bodner T., Brandauer E., Benke T., Weirich-Schwaiger H., Poewe W., and Wenning G.K. Riluzole in Huntington's disease (HD): an open label study with one year follow up. J. Neurol. 248 (2001) 866-869
124. Smith D.L., Woodman B., Mahal A., Sathasivam K., Ghazi-Noori S., Lowden P.A., Bates G.P., and Hockly E. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann. Neurol. 54 (2003) 186-196
125. 10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 1762 (2006) 616-626
126. Spires T.L., Grote H.E., Varshney N.K., Cordery P.M., van Dellen A., Blakemore C., and Hannan A.J. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J. Neurosci. 24 (2004) 2270-2276
127. Squitieri F., Cannella M., and Simonelli M. CAG mutation effect on rate of progression in Huntington's disease. Neurol. Sci. 23 (2002) S107-S108
128. Stack E.C., Kubilus J.K., Smith K., Cormier K., Del Signore S.J., Guelin E., Ryu H., Hersch S.M., and Ferrante R.J. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol. 490 (2005) 354-370
129. 10 in R6/2 transgenic Huntington's disease mice. Biochim. Biophys. Acta 1762 (2006) 373-380
130. Stack E.C., Dedeoglu A., Smith K.M., Cormier K., Kubilus J.K., Bogdanov M., Matson W.R., Yang L., Jenkins B.G., Luthi-Carter R., Kowall N.W., Hersch S.M., Beal M.F., and Ferrante R.J. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J. Neurosci. 27 (2007) 12908-12915
131. Stack E.C., Del Signore S.J., Luthi-Carter R., Soh B.Y., Goldstein D.R., Matson S., Goodrich S., Markey A.L., Cormier K., Hagerty S.W., Smith K., Ryu H., and Ferrante R.J. Modulation of nucleosome dynamics in Huntington's disease. Hum. Mol. Genet. 16 (2007) 1164-1175
132. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., Kazantsev A., Schmidt E., Zhu Y.Z., Greenwald M., Kurokawa R., Housma D.E., Jackson G.R., Marsh J.L., and Thompson L.M. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413 (2001) 739-743
133. Tanaka M., Machida Y., Niu S., Ikeda T., Jana N.R., Doi H., Kurosawa M., Nekooki M., and Nukina N. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10 (2004) 148-154
134. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
135. Thomas M., Ashizawa T., and Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov. Disord. 19 (2004) 692-695
136. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., and Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8093-8097
137. van Dellen A., Blakemore C., Deacon R., York D., and Hannan A.J. Delaying the onset of Huntington's in mice. Nature 404 (2000) 721-722
138. van Dellen A., Deacon R., York D., Blakemore C., and Hannan A.J. Anterior cingulate cortical transplantation in transgenic Huntington's disease mice. Brain. Res. Bull. 56 (2001) 313-318
139. van Praag H., Christie B.R., Sejnowski T.J., and Gage F.H. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13427-13431
140. Verbessem P., Lemiere J., Eijnde B.O., Swinnen S., Vanhees L., Van Leemputte M., Hespel P., and Dom R. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 61 (2003) 925-930
141. Wang X., Zhu S., Drozda M., Zhang W., Stavrovskaya I.G., Cattaneo E., Ferrante R.J., Kristal B.S., and Friedlander R.M. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10483-10487
142. Wang W., Duan W., Igarashi S., Morita H., Nakamura M., and Ross C.A. Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. Neurobiol. Dis. 20 (2005) 500-508
143. Wang X., Sarkar A., Cicchetti F., Yu M., Zhu A., Jokivarsi K., Saint-Pierre M., and Brownell A.L. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J. Neurol. Sci. 231 (2005) 57-66
144. Wang Y.L., Liu W., Wada E., Murata M., Wada K., and Kanazawa I. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci. Res. 53 (2005) 241-249
145. Warrick J.M., Chan H.Y., Gray-Board G.L., Chai Y., Paulson H.L., and Bonini N.M. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 23 (1999) 425-428
146. Wellington C.L., Ellerby L.M., Hackam A.S., Margolis R.L., Trifiro M.A., Singaraja R., McCutcheon K., Salvesen S., Propp S.S., Bromm M., Rowland K.J., Zhang T., Rasper D., Roy S., Thornberry N., Pinsky L., Kakizuka A., Ross C.A., Nicholson D.W., Bredesen D.E., and Hayden M.R. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273 (1998) 9158-9167
147. Wild E.J., and Tabrizi S.J. Predict-HD and the future of therapeutic trials. Lancet Neurol. 5 (2006) 724-725
148. Wood N.I., and Morton A.J. Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res. Bull. 61 (2003) 375-383
149. Wood N.I., Pallier P.N., Wanderer J., and Morton A.J. Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice. Neurobiol. Dis. 25 (2007) 342-353
150. Yamamoto A., Lucas J.J., and Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101 (2000) 57-66
151. Yang C.R., and Yu R.K. Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease. J. Neurosci. Res. 87 (2009) 26-33
152. Young D., Lawlor P.A., Leone P., Dragunow M., and During M.J. Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nat. Med. 5 (1999) 448-453
153. Yu Z.X., Li S.H., Evans J., Pillarisetti A., Li H., and Li X.J. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci. 23 (2003) 2193-2202
154. Zhang Y., Ona V.O., Li M., Drozda M., Dubois-Dauphin M., Przedborski S., Ferrante R.J., and Friedlander R.M. Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington's disease. J. Neurochem. 87 (2003) 1184-1192
155. Zhang X., Smith D.L., Meriin A.B., Engemann S., Russel D.E., Roark M., Washington S.L., Maxwell M.M., Marsh J.L., Thompson L.M., Wanker E.E., Young A.B., Housman D.E., Bates G.P., Sherman M.Y., and Kazantsev A.G. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 892-897
156. Zourlidou A., Gidalevitz T., Kristiansen M., Landles C., Woodman B., Wells D.J., Latchman D.S., de Belleroche J., Tabrizi S.J., Morimoto R.I., and Bates G.P. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation. Hum. Mol. Genet. 16 (2007) 1078-1090
157. Zucker B., Ludin D.E., Gerds T.A., Lücking C.H., Landwehrmeyer G.B., and Feuerstein T.J. Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease. Naunyn Schmiedebergs Arch. Pharmacol. 370 (2004) 131-139
158. Zucker B., Luthi-Carter R., Kama J.A., Dunah A.W., Stern E.A., Fox J.H., Standaert D.G., Young A.B., and Augood S.J. Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum. Mol. Genet. 14 (2005) 179-189